Skip to main content

Table 8 Subgroup analysis based on different dose schedule of cisplatin to compare the toxicities of CCRT and CCRT with cetuximab

From: Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case–control study

  Toxic effects received weekly cisplatin, No. (%) p value*
CCRT +Cetuximab(n = 23) CCRT alone(n = 60)
All Grades Grade3 ~ 4 All Grades Grade3 ~ 4 All Grades Grade3 ~ 4
Leucopenia 14 4 49 11 0.047 1
Neutropenia 13 2 32 5 0.794 1
Anaemia 4 1 36 1 0.001 0.48
Thrombocytopenia 3 1 20 3 0.065 1
AST increased 3 0 10 0 0.945
ALT increased 15 1 17 1 0.002 0.48
BUN 0 0 4 0 0.486
CRE 0 0 0 0
Mucositis 23 7 58 13 0.931 0.403
Dermatitis 17 1 50 4 0.507 1
Vomiting 17 2 24 0 0.006 0.074
Weight loss 20 1 54 0 0.996 0.277
  Toxic effects received triweekly cisplatin, No. (%) p value*
CCRT +Cetuximab(n = 39) CCRT alone(n = 64)
All Grades Grade3 ~ 4 All Grades Grade3 ~ 4 All Grades Grade3 ~ 4
Leucopenia 28 4 54 8 0.124 0.978
Neutropenia 21 2 37 4 0.694 1
Anaemia 6 1 33 1 < 0.001 1
Thrombocytopenia 6 0 14 2 0.419 0.525
AST increased 7 0 10 0 0.758
ALT increased 21 0 18 1 0.009 1
BUN 3 0 6 0 1
CRE 2 0 13 0 0.034
Mucositis 39 25 61 16 0.442 < 0.001
Dermatitis 37 2 54 1 0.196 0.66
Vomiting 32 1 42 2 0.072 1
Weight loss 37 1 51 0 0.034 0.379
  1. Data are n or n (%). *p values were calculated with the χ2 test (or Fisher’s exact test). †According to the Common Terminology Criteria for Adverse Events (version 4.0) weight loss has only grade 1–3